SEARCH

SEARCH BY CITATION

References

  • 1
    Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000; 32:141156.
  • 2
    Viallet A, Marleau D, Huet M, Martin F, Farley A, Villeneuve JP, Lavoie P. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 1975; 69:12971300.
  • 3
    Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985; 5:419424.
  • 4
    Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage [Comments]. Gastroenterology 1990; 99:14011407.
  • 5
    Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, Morel I, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996; 111:701709.
  • 6
    Armonis A, Patch D, Burroughs A. Hepatic venous pressure measurement: an old test as a new prognostic marker in cirrhosis? Hepatology 1997; 25:245248.
  • 7
    Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, Rodes J. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995; 346:10561059.
  • 8
    Escorsell A, Bordas JM, Castaneda B, Llach J, Garcia-Pagan JC, Rodes J, Bosch J. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31:10611067.
  • 9
    Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Torras X, Cusso X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996; 334:16241629.
  • 10
    Villanueva C, Minana J, Ortiz J, Gallego A, Soriano G, Torras X, Sainz S, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345:647655.
  • 11
    Teres J, Bosch J, Bordas JM, Garcia Pagan JC, Feu F, Cirera I, Rodes J. Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial. Gastroenterology 1993; 105:15081514.
  • 12
    McCormick PA, Feu F, Sabrin C, Planas R, Anglo-Spanish variceal rebleeding group. Propranolol and isosorbide mononitrate versus sclerotherapy or shunt surgery for the prevention of variceal rebleeding: a randomized trial. Hepatology 1994; 20:106A.
  • 13
    Escorsell A, Banares R, Garcia-Pagan JC, Gilabert R, Moitinho E, Piqueras B, Bru C, et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 2002; 35:385392.
  • 14
    Bosch J, Mastai R, Kravetz D, Navasa M, Rodes J. Hemodynamic evaluation of the patient with portal hypertension. Semin Liver Dis 1986; 6:309317.
  • 15
    de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000; 33:846852.
  • 16
    Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164176.
  • 17
    Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000; 32:142153.
  • 18
    Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464470.
  • 19
    Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, Gatta A. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000; 32:930934.
  • 20
    Casado M, Bosch J, Garcia-Pagan JC, Bru C, Banares R, Bandi JC, Escorsell A, et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114:12961303.
  • 21
    Abraczinskas DR, Ookubo R, Grace ND, Groszmann RJ, Bosch J, Garcia-Tsao G, Richardson CR, et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Hepatology 2001; 34:10961102.
  • 22
    Garcia-Pagan JC, Escorsell A, Moitinho E, Bosch J. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999; 19:427438.
  • 23
    Mills PR, Rae AP, Farah DA, Russell RI, Carter DC. Comparison of three adrenoceptor blocking agents in patients with cirrhosis and portal hypertension. Gut 1984; 25:7378.
  • 24
    Hillon P, Lebrec D, Muñoz C, Jungers M, Goldfarb G, Banhamou JP. Comparison of the effects of a cardioselective and a nonselective β-blocker on portal hypertension in patients with cirrhosis. Hepatology 1982; 2:528531.
  • 25
    Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, Rodes J. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984; 4:12001205.
  • 26
    Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJ, Morse SS, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986; 6:101106.
  • 27
    Garcia-Pagan JC, Feu F, Bosch J, Rodes J. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med 1991; 114:869873.
  • 28
    Banares R, Moitinho E, Piqueras B, Casado M, Garcia-Pagan JC, de Diego A, Bosch J. Carvedilol, a new nonselective β-blocker with intrinsic anti-Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology 1999; 30:7983.
  • 29
    Albillos A, Lledo JL, Rossi I, Perez-Paramo M, Tabuenca MJ, Banares R, Iborra J, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. Gastroenterology 1995; 109:12571265.
  • 30
    Albillos A, Garcia-Pagan JC, Iborra J, Bandi JC, Cacho G, Perez-Paramo M, Escorsell A, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998; 115:116123.
  • 31
    Luca A, Garcia-Pagan JC, Feu F, Lopez-Talavera JC, Fernandez M, Bru C, Bosch J, et al. Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis. Hepatology 1995; 21:8388.
  • 32
    Merkel C, Sacerdoti D, Bolognesi M, Bombonato G, Gatta A. Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. J Hepatol 1998; 28:622630.